Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


A critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.

Christensen M, Najy AJ, Snyder M, Movilla LS, Kim HR.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):151-8. doi: 10.1016/j.ijrobp.2013.10.019.


PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.

Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28.


Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Najy AJ, Won JJ, Movilla LS, Kim HR.

Mol Cancer Res. 2012 Aug;10(8):1087-97. doi: 10.1158/1541-7786.MCR-12-0071. Epub 2012 Jun 11.


Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function.

Kim HE, Han SJ, Kasza T, Han R, Choi HS, Palmer KC, Kim HR.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):731-6.


Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, Kennedy RD, Salto-Tellez M, Albanese C, Waugh DJ.

Eur Urol. 2013 Aug;64(2):177-88. doi: 10.1016/j.eururo.2012.08.032. Epub 2012 Aug 28.


Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.

Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH.

Stem Cells. 2008 Jun;26(6):1425-35. doi: 10.1634/stemcells.2007-1076. Epub 2008 Apr 10.


Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.

Isebaert SF, Swinnen JV, McBride WH, Haustermans KM.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):239-47. doi: 10.1016/j.ijrobp.2011.03.030.


Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.

Clin Cancer Res. 1997 Jul;3(7):1167-77.


Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.

Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H.

Cancer Res. 2007 Jul 1;67(13):6083-91.


miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH.

Stem Cells. 2009 Aug;27(8):1712-21. doi: 10.1002/stem.101.


PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR.

Mol Cancer. 2013 Jul 31;12(1):85. doi: 10.1186/1476-4598-12-85.


Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.

Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M.

Hepatology. 2013 Sep;58(3):1042-53. doi: 10.1002/hep.26384. Epub 2013 Jul 22.


PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.


Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.

Kim S, Huang W, Mottillo EP, Sohail A, Ham YA, Conley-Lacomb MK, Kim CJ, Tzivion G, Kim HR, Wang S, Chen YQ, Fridman R.

Biochim Biophys Acta. 2010 Nov;1803(11):1287-97. doi: 10.1016/j.bbamcr.2010.06.011. Epub 2010 Jul 8.


Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.

Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V, Camacho D, Simpson RM, Kelly K.

Am J Pathol. 2011 Jul;179(1):422-35. doi: 10.1016/j.ajpath.2011.03.035. Epub 2011 May 13.


A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.

Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR.

Cancer Res. 2010 Dec 1;70(23):9631-40. doi: 10.1158/0008-5472.CAN-10-0511. Epub 2010 Nov 23.


Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk